Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

Eva Comperat, MD
Published: Friday, Oct 06, 2017



Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Patients who have NETs are generally more benign cases, making it important to treat them differently, states Comperat. There are patients who will metastasize, so it is crucial for the pathologist to make the right diagnosis and for the medical oncologist to understand how to best treat these patients.

There are new data about the molecular biology of the tumor. There are 2 subgroups of NETs, one of which is more genetically unstable. Having different strategies for these tumors will benefit the patients, explains Comperat.
 


Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Patients who have NETs are generally more benign cases, making it important to treat them differently, states Comperat. There are patients who will metastasize, so it is crucial for the pathologist to make the right diagnosis and for the medical oncologist to understand how to best treat these patients.

There are new data about the molecular biology of the tumor. There are 2 subgroups of NETs, one of which is more genetically unstable. Having different strategies for these tumors will benefit the patients, explains Comperat.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x